{
    "nctId": "NCT04367090",
    "briefTitle": "Pharmacokinetic Study of Pyrotinib and Docetaxel in Combination With Trastuzumab in Patients With HER2 Metastatic Breast Cancer",
    "officialTitle": "An Open, Single-arm and Multi-center Pharmacokinetic Study of Pyrotinib and Docetaxel Plus Trastuzumab in Patients With HER2 Positive Recurrent or Metastasis Breast Cancer.",
    "overallStatus": "COMPLETED",
    "conditions": "Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 97,
    "primaryOutcomeMeasure": "Pharmacokinetic parameter: Cmax of pyrotinib and docetaxel",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. HER2 positive recurrent or metastasis breast cancer.\n2. Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n3. Adequate organ function.\n4. Signed, written inform consent obtained prior to any study procedure.\n\nExclusion Criteria:\n\n1. Patients received more than 1 line of chemotherapy or immunotherapy in the phase of recurrence / metastasis.\n2. History of HER tyrosine kinase inhibitors or monoclonal antibody for breast cancer in any treatment setting\uff0cexcept trastuzumab ,or Pertuzumab used in the neo-adjuvant or adjuvant setting.\n3. Assessed by the investigator to be unable receive systemic chemotherapy.\n4. History of other malignancy within the last 5 years\uff0cexcept for carcinoma in situ of cervix\uff0cbasal cell carcinoma or squamous cell carcinoma of the skin that has been previously treated with curative intent.\n5. Pregnant or lactating women\uff0cor for women of childbearing potential unwilling to use a highly-effective contraception during of the study treatment and for at least 7 months after the last dose of study treatment.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}